2020-2023 (Grant): Evaluating Multidisciplinary Bone Marrow Failure Syndrome Care – a prospective observational clinical trial offering comprehensive diagnostic genomic evaluation, multidisciplinary case review and multidisciplinary clinical care.
One of the most important initial steps in treating patients with bone marrow failure is getting the right diagnosis. In patients that are suspected to have an inherited bone marrow failure syndrome, complex genetic testing is required to reach the correct diagnosis. The EMBRACE clinical trial aims to measure the impact of providing Australian patients with bone marrow failure an accurate genetic diagnosis, up-to-date and comprehensive information about the disease, and access to treatment and clinical trials. The impact will be measured by evaluating patient outcomes, quality of life and health economic benefits for those receiving care under the EMBRACE study.
By ensuring that Australian patients have access to both the diagnostic and treatment expertise they need, it is hoped that EMBRACE will improve patient outcomes and understanding of these rare disorders.
2020-2025 (Grant): The Australian Bone Marrow Failure Biobank. Professor Melissa Southey, Biobanking Victoria, Monash University. The establishment of the Australian Marrow Failure Biobank, led by Maddie Riewoldt’s Vision, is a collaboration ...
Read more2020-2024 (Grant): Rescuing bone marrow function in relapsed acquired Aplastic Anaemia and /or poor graft function post allogeneic bone marrow transplantation, Professor David Ritchie, Melbourne Health. Clinical trials are important for the ...
Read more2021-2024 (Grant-in-Aid): Precision gene editing for the treatment of Fanconi Anaemia. Dr Lorna McLeman, St Vincent’s Institute of Medical Research. Fanconi Anaemia is the most common cause of inherited bone marrow failure with a median onset of ...
Read more2019-2023 (Co-funded VCA/Maddie Riewoldt’s Vision International Travelling Fellowship): Novel immunological assessment of Aplastic Anaemia and post transplant Graft Dysfunction for the purposes of targeted therapeutic intervention. Dr ...
Read more